- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
A half-life of approximately 6.2 to 8.7 hours has been reported in pediatric subjects with chronic renal failure after multiple intravenous administration of erythropoietin. The pharmacokinetic profile of erythropoietins in children and adolescents appears to be similar to that in adults.
There are limited pharmacokinetic data in neonates. A study in 7 very low birth weight preterm neonates and in 10 healthy adults to whom erythropoietin was given intravenously suggested that the volume of distribution was about 1.5 to 2 times higher in the preterm neonates than in the healthy adults, and that clearance was about 3 times higher in the preterm neonates than in healthy adults.
(SmPC Retocrit)
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Anaemia due to chronic renal insufficiency with haemodialysis |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
The side effect profile in children is similar to that of adults.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Other antianemic preparations | ||
|---|---|---|
| B03XA02 | ||
| B03XA01 | ||
| B03XA01 | ||
| B03XA03 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Pfizer Europe MA EEIG, SmPC Retacrit (EU/1/07/431) Rev 30, 14-12-2022, www.ema.europa.eu
- Kidney Disease: Improving Global Outcomes (KDIGO), Clinical practice guidelines: Anemia in Chronic Kidney Disease, 2012, 2 (4)
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
